Form 4: Travere Therapeutics Director Ron Squarer Reports Acquisition of Shares and Stock Options

Director Ron Squarer reported acquiring 6,500 shares of common stock and 19,500 stock options in Travere Therapeutics, Inc. on May 8, 2024.

Summary

• On May 8, 2024, Ron Squarer, a director of Travere Therapeutics, Inc., acquired 6,500 shares of common stock.
• These shares were acquired at a price of $0.
• Following this transaction, Squarer directly owns 28,875 shares of common stock.
• Squarer also acquired 19,500 stock options with an exercise price of $6.82.
• These options vest over a one-year period and expire on May 7, 2034.
• The acquisition was an automatic equity grant under the company's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard compensation practices and insider confidence, but doesn't contain groundbreaking news.

Positives

• The acquisition of shares and options by a director signals confidence in the company's future.

Future Outlook

The document does not contain specific forward-looking statements, but the equity grant suggests a continued relationship between the director and the company.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding director's holdings.

Key Dates